Serotonin receptor changes in depression: Evidences and limitations;Alteraciones de los receptores serotoninérgicos en la depresión: Evidencias y limitaciones

Actas Espanolas de Psiquiatria

Volumn 29, Issue 3, 2001, Pages 186-194

  Gomez E ^a   Catalan R ^a   Navines R ^a   Gasto C ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

5 HT1A receptors; 5 HT2A receptors; Depression; Platelet; Serotonergic markers; Serotonin

Indexed keywords

SEROTONIN RECEPTOR;

BRAIN; DEPRESSION; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; THROMBOCYTE;

BLOOD PLATELETS; BRAIN; DEPRESSIVE DISORDER; HUMANS; RECEPTORS, SEROTONIN;

EID: 0035344931     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. Jefferson JW, Greist JH. Trastornos del estado de ánimo. En: Hales RE, Yudofsky SC, Talbott JA, eds. Tratado de Psiquiatría. Barcelona: Ancora SA; 1996. p. 491-522.
2. Maes M, Meltzer HY. The serotonin hypothesis of major depression. En: Bloom FE, Kupfer DJ, eds. Psychopharmacology, The fourth generation of progress. Lippincott-Raven New Jersey: Healthcare; 1995. p. 933-44.
3. Cuenca E, Coullaut-Jáuregui J, López-Muñoz F, Álamo C. Serotonina y depresión. Psiquiatría Biol 1996;2: 53-70.
4. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998;59(Supl 14):11-4.
5. Mann JJ. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacol 1999;21: NO. 2S.
6. Berman RM, Charney DS. Models of antidepressant action. J Clin Psychiatry 1990;60(Supl 14):16-20.
7. Schildkraut JJ. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 1965;122:509-22.
8. Bunney WE, Davis JM. Norepinephrine in depressive reactions: A review. Arch Gen Psychiatry 1965;13: 483-94.
9. Coppen A, Prange AJ, Jr. Hill C, Whybrow PC, Noguera R. Abnormalities of indolamines in affective disorders. Arch Gen Psychiatry 1972;26:474-8.
10. Axelrod J, Weil-Malherve H, Tomchick R. The physiologycal disposition of 3H-epinephrine and its metabolite, metanephrine. J Pharmacol Exp Ther 1959; 127:251-6.
11. Syvälahti EKG. Biological aspects of depression. Acta Psychiatr Scand 1994;(Supl 377):11-5.
12. Arranz B, San L, Rosel P, Callado LF, Meana JJ. La neurotransmisión monoaminérgica en el suicidio. El sistema serotoninérgico. Psiquiatría Biol 1997;5: 205-12.
13. Asberg M, Bertilsson L, Martensson B, Scanlia-Tomba GP, Thorén P, Träskman-Bendz L. CSF monoamine metabolites in melancholia. Acta Psychiatry Scand 1984;69:201-19.
14. Delgado PL, Price LH, Heninger GF, Charney DS. Neurochemistry. En: Paykel ES, ed. Handbook of affective disorders. London: Churchill Livingstone; 1992. p. 219-53.
15. Potter WZ, Manji-HK. Catecholamines in depression: an update. Clin Chem 1994;40:279-87.
16. Ellis PM, Salmond C. Is platelet imipramine binding reduced in depression? A Meta-Analysis. Biol Psychiatry 1994;36:292-9.
17. Gómez Gil E, Martínez de Osaba MJ, Gastó Ferrer C. Pruebas neuroendocrinas de función serotoninérgica y estudios en depresión. Psiquiatría Biol (Barcelona) 1996;3:142-51.
18. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 1992;229:101-3.
19. Asberg M, Thoren L, Traskman P. Serotonin depression: a biochemical subgroup within the affective disorders. Science 1976;191:478-80.
20. Träskman-Bendz L, Alling C, Alsén M, Regnéll G, Simonsson P. The role of monoamines in suicidal behavior. Acta Psychiatr Scand 1993;(Supl 371):45-7.
21. Cuenca E, Alamo C, Coullaut Jáuregui. Antidepresivos: clasificación y mecanismo de acción. Rev Clin Esp 1997;197:50-3.
22. Sulser F, Vetulani J, Mobley PL. Mode of action of antidepressant drugs. Biochem Pharmacol 1978;27: 257-61.
23. Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Arch Gen Psychiatry 1981;38: 1160-80.
24. Heninger GR, Charney DS. Mechanism of action of antidepressant treatment: implications for the etiology and treatment of depressive disorders. En: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press; 1987. p. 535-43.
25. Yatham LN, Steiner M. Neuroendocrine probes of serotonergic function: A critical review. Life Sci 1993; 53:447-63.
26. Cowen PJ, Anderson IM, Grahame-Smith DG. Neuroendocrine effects of azapirones. J Clin Psychopharmacol 1990;10(Supl 3):21S-5S.
27. Stahl SM, Hauger RL, Rausch JL, Fleishaker JC, Hubbell-Alberts EA. Down regulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: Neuroendocrine and platelet markers. Clin Neuropharmacol 1993;16:519-31.
28. Wirz-Justice A. Platelet research in psychiatry. Experientia 1988;44:145-51.
29. Da Prada M, Cesura AM, Launay JM, Richards JG. Platelets as a model for neurones? Experientia 1988;44: 115-26.
30. Pletscher A. Platelets as models: Use and limitations. Experientia 1988;44:152-5.
31. Anders AH, Rao ML, Ostrowitzki S, Entzian W. Human brain cortex and platelet serotonin-2 receptor binding properties and their regulation by endogenous serotonin. Life Sci 1993;52:313-21.
32. Hrdina PD. Platelet serotonergic markers in psychiatric disorders: use, abuse and limitations. J Psychiatry Neurosci 1994;19:87-8.
33. McBride PA, Mann JJ, Polley MJ, Wiley AJ, Sweeney JA. Assessment of binding indices and physiological responsiveness of the 5-HT2 receptor on human platelets. Life Sci 1987;40:1799-809.
34. Geaney DP, Schacter M, Elliot JM, Graham-Smith DG. Characterisation of 3-H-lysergic acid diethylamide binding to a 5-hydroxytryptamine receptor on human platelet membranes. Eur J Pharmacol 1984;97: 87-93.
35. Pandey GN, Pandey SC, Dwivedi Y, Sharma RP, Janicak PG, Davis JM. Platelet serotonin 2A receptors: A potential biological marker for suicidal behavior. Am J Psychiatry 1995;152:850-5.
36. Pandey SC, Davis J, Pandey GN. Phosphoinositide system linked serotonin receptor subtypes and their pharmacological properties and clinical correlates. J Psychiatry Neurosci 1995;20:3:215-25.
37. Alarayyed NA, Grama BR, Prichard BNC, Smith CCT. The potentiation of adrenaline-induced in vitro platelet aggregation by ADP, collagen and serotonin and its inhibition by naftopidil and doxazosin in normal human subjects. Br J Pharmacol 1995;39:369-74.
38. Vanags DM, Rodgers SE, Duncan EM, Lloyd JV, Bochner JVL. Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline. Br J Pharmacol 1992;106:917-23.
39. Cerrito F, Lazzaro MP, Gaudio E, Arminio P, Aloisi G. 5-HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci 1993;3:209-15.
40. Brazell C, McClue SJ, Preston GC, King B, Stahl SM. 5-Hydroxytryptamine (5-HT)-induced shape change in human platelets determined by computerized data acquisition: correlation with [125]-iodoLSD binding at 5-HT2 receptors. Blood Coagul Fibrinolysis 1991; 2:17-24.
41. Erne P, Pletscher A. Rapid intracellular release of calcium in human platelets by stimulation of 5-HT2 receptors. Br J Pharmacol 1985;84:545-9.
42. Pacheco MA, Stockmeier C, Meltzer HY, Overholser JC, Dilley GE, Jope RS. Alterations in phosphoinositide signaling and G-protein levels in depressed suicide brain. Brain Res 1996;723:37-45.
43. Mikuni M, Kusimi I, Kagaya A, Kuroda Y, Mori H, Takahashi K. Increased 5-HT2 receptor function as measured by serotonin stimulated phosphoinositide hydrolysis in platelets of depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:49-61.
44. Cheetham SC, Crompton MR, Katona CLE, Horton RW. Brain 5-HT1 binding sites in depressed suicides. Psychopharmacology 1990;102:544-8.
45. 1A receptor binding in the human brain postmortem: effects of age and alcohol. Brain Res 1991;544-8.
46. Arranz B, Eriksson A, Mellerup E, Plenge P, Marcusson J. Brain 5-HT1A, 5-HT1D, and 5-HT2 receptors in suicide victims. Biol Psychiatry 1994;35:457-63.
47. Lowther S, De Parmentier F, Cheetham SC, Crompton MR, Katona CLE, Horton RW. 5-HT1A receptor binding sites in postmortem brain samples from depressed suicides and controls. J Affect Disord 1997; 42:199-207.
48. Matsubara S, Arora RC, Meltzer HY. Serotonergic measures in suicide brain: 5-HT1A binding sites in frontal cortex of suicide victims. J Neural Transm 1991; 85:181-94.
49. Stockmeier CA, Shapiro LA, Dilley GE, Kolli TM, Friedman L, Rajkowska G. Increase on serotonin-1A autoreceptors in the midbrain of suicide victims with major depression. Postmortem evidence for decreased serotonin activity. J Neurosci 1998;18: 7394-401.
50. Mobayed M, Dinan TG. Buspirone/prolactin response in post head injury depression. J Affec Disord 1990;19:237-41.
51. Lesch KP, Mayer S, Disselkamp-Tietze J, Hoh A, Wiesmann M, Osterheider M, Schulte HM. 5-HT1A receptor responsivity in unipolar depression. Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatry 1990;28:620-8.
52. Moeller FG, Steinberg JL, Fulton M, Kramer G, Petty F. A preliminary neuroendocrine study with buspirone in major depression. Neuropsychopharmacology 1994;10:75-83.
53. Meltzer HY, Maes M. Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects. Biol Psychiatry 1994;35:316-23.
54. Cowen PJ, Power AC, Ware CJ, Anderson MI. 5-HT1A receptor sensitivity in major depression. A neuroendocrine study with buspirone. Br J Psychiatry 1994; 164:372-9.
55. Stanley M, Mann JJ. Increased serotonin 2-binding sites in frontal cortex of suicide victims. Lancet 1983;I:214-6.
56. Mann JJ, Stanley M, McBride PA, McEwen BS. Increased serotonin-2 and beta-adrenergic receptor binding in the frontal cortex of suicide victims. Arch Gen Psychiatry 1986;43:945-59.
57. Ferrier IN, McKeith IG, Cross AJ, Perry EK, Candy JM, Perry RH. Postmortem neurochemistry. Biol Psychiatry 1996;39:1044-50.
58. Arora RC, Meltzer HY. Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. Am J Psychiatry 1989;146:730-6.
59. Yates M, Leake A, Candy JM, Fairbairn AF, McKeith IG, Ferrier IN. 5-HT2 receptor changes in major depression. Biol Psychiatry 1990;27:489-58.
60. Arango V, Ernsberger P, Marzuk PM, Chen JS, Tierney H, Stanley M, Reiss DJ, Mann J. Autoradiographic demonstration of increased serotonin 5-HT2 and ßadrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 1990;47:1037-47.
61. Arango V, Underwood MD, Mann JJ. Alterations in monoamine receptors in the brain of suicide victims. J Clin Psychopharmacol 1992;12:8-12.
62. Hrdina PD, Demeter E, Vu TB, Sotonyi P, Palkovits M. 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Res 1993;614:37-44.
63. Rosel P, Arranz B, Vallejo J, Oros M, Crespo JM, Menchon JM, Navarro MA. Variations in [3H] imipramine and 5-HT2A but not [3H] paroxetine binding sites in suicide brains. Psychiatry Res 1998;82:161-70.
64. Owen F, Cross AJ, Crow TJ. Brain 5-HT2 receptors and suicide. Lancet 1983;2:1256.
65. Cheetham SC, Crompton MR, Katona CLE, Horton RW. Brain 5-HT2 receptor binding sites in depressed suicide victims. Brain Res 1988;443:272-80.
66. Gross-Isseroff R, Salama D, Israeli M, Biegon A. Autoradiographic analysis of [3H] ketanserin binding in the human brain postmortem: Effect of suicide. Brain Res 1990;507:208-15.
67. Arora RC, Meltzer HY. Increased serotonin-2 (5-HT2) receptor binding as measured by 3-H-lysergic acid diethylamide 5-H-LSD in the blood platelets of depressed patients. Life Sci 1989;44:725-34.
68. Biegon A, Weizman A, Karp L, Ram A, Tiano S, Wolff M. Serotonin 5-HT2 receptor binding in blood platelets-A peripheral marker for depression? Life Sci 1987;41:2485-92.
69. Biegon A, Grinspoon A, Blunienfelt B, Bleich A, Apter A, Mester R. Increased serotonin 5-HT receptor binding on blood platelets of suicidal men. Psychopharmacology 1990;100:165-7.
70. Pandey GN, Pandey SC, Janicak PG, Marks RC, Davis JM. Platelet serotonin-2 receptor binding sites in depression and suicide. Biol Psychiatry 1990;28: 215-22.
71. Hrdina PD, Bakish D, Chudzik J, Ravindran A, Lapierre YD. Serotonergic markers in platelets of patients with major depression: Upregulation of 5-HT2 receptors. J Psychiatry Neurosci 1995;20:11-9.
72. Bakish D, Cavazzoni P, Chudzik J, Ravindram A, Hrdina PD. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol Psychiatry 1997;41: 184-90.
73. Serres F, Azorin JM, Valli M, Jeanningros R. Evidence for an increase in functional platelet 5-HT2A receptors in depressed patients using the new ligand [125I]-DOI. Eur Psychiatry 1999;14:451-7.
74. Cowen PJ, Charig EM, Fraser LS, Elliott JM. Platelet 5-HT receptor binding during depressive illness and tricyclic antidepressant treatment. J Affect Disord 1987;13:45-50.
75. McBride PA, Brown RP, DeMeo M, Keilp J, Mieczkowski T, Mann JJ. The relationship of platelet 5-HT2 receptor indices to major depressive disorder, personality traits, and suicidal behaviour. Biol Psychiatry 1994;35:295-308.
76. Asnis GM, Eisenberg J, van Praag HM, Lemus CZ, Friedman JMH, Miller AH. The neuroendocrine response to fenfluramine in depressives and normal controls. Biol Psychiatry 1988;24:117-20.
77. Weizman A, Mark M, Gil-Ad I, Tyano S, Laron Z. Plasma cortisol, prolactin, growth hormone and immunoreactive beta-endorphin response to fenfluramine challenge in depressed patients. Clin Neuropharmacol 1988;11:250-6.
78. Maes M, D'Hondt P, Suy E, Minner B, Vandervorst C, Raus J. HPA-axis hormones and prolactin response to dextrofenfluramine in depressed patients and healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:781-90.
79. Siever LJ, Uhde TW, Jimerson DC, Lake CR, Silberman ER, Post RM, Murphy DL. Differential inhibitory noradrenergic responses to clonidine in 25 depressed patients and 25 normal control subjects. Am J Psychiatry 1984;141:733-41.
80. Shapira B, Reiss A, Kaiser N, Kindler S, Lerer B. Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients. J Affect Disord 1989;16:1-4.
81. Mitchell P, Smythe G. Hormonal responses to fenfluramine in depressed and control subjects. J Affect Disord 1990;19:43-51.
82. O'Keane V, Dinan TG. Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. Am J Psychiatry 1991;148:1009-15.
83. O'Keane V, McLoughlin D, Dinan TG. D-fenfluramine-induced prolactin and cortisol release in major depression: response to treatment. J Affect Disord 1992;26:143-50.
84. Lichtenberg P, Shapira B, Guillon D, Kindler S, Cooper TB, Newman ME. Hormone responses to fenfluramine and placebo challenge in endogenous depression. Psychiatry Res 1992;43:137-46.
85. Flory JD, Mann JJ, Manuck SB, Muldoon MF. Recovery from major depression is not associated with normalization of serotonergic function. Biol Psychiatry 1998;43:320-6.
86. Healy DT, Carney PA, O'Halloran A, Leonard BE. Peripheral adrenoceptors and serotonin receptor in depression. J Affect Disord 1985;9:285-96.
87. Butler J, Leonard BE. The platelet serotonergic system in depression and following sertraline treatment. Int Clin Psychopharmacol 1988;3:343-7.
88. McAdams C, Leonard BE. Changes in platelet aggregatory responses to collagen and 5-hydroxytryptamine in depressed, schizophrenic and manic patients. Int Clin Psychopharmacol 1992;7:81-5.
89. Wood K, Swade C, Abou-Saleh M, Coppen A. Peripheral serotonergic receptor sensitivity in depressive illness. J Affect Disord 1984;7:59-65.
90. Gómez E, Escolar G, Díaz-Ricard M, Gastó C. Modificaciones del funcionalismo de los receptores plaquetarios 5-HT2A tras tratamiento antidepresivo en la depresión mayor evaluadas mediante la respuesta de agregación plaquetaria amplificada con serotonina. Jornadas de Clausura de la Sociedat Catalana de Psiquiatría. Montbrio 18 y 19 de junio; 1998.
91. Brusov O, Beliaev BS, Katasonov AB, Zlobina GL, Factor MI, Lideman RR. Does platelet serotonin supersensitivity accompany endogenous depression? Biol Psychiatry 1989;25:375-81.
92. Kusumi I, Koyama T, Yamashita I. Serotonin-stimulated Ca2+ response is increased in the blood platelets of depressed patients. Biol Psychiatry 1991;30:310-2.
93. Mikuni M, Kagaya A, Takahashi K, Meltzer HY. Serotonin but not norepinephrine-induced calcium mobilisation of platelets is enhanced in affective disorders. Psychopharmacology 1992;106:311-4.
94. Eckert A, Gann H, Riemann D, Aldenhoff J, Muller WE. Elevated intracellular calcium levels after 5-HT3 receptor stimulation in platelets of depressed patients. Biol Psychiatry 1993;34:565-8.
95. Yamawaki S, Kagaya A, Okamoto Y, Shimizu M, Nishida A, Uchitomi Y. Enhanced calcium response to serotonin in platelets from patients with affective disorders. J Psychiatry Neurosci 1996;21:321-4.
96. Konopka LM, Cooper R, Crayton JW. Exaggerated response to serotonin of platelet cytosolic calcium in depressed, schizophrenic, and substance abuse patients. Biol Psychiatry 1996;39:708-13.
97. Delisi SM, Konopka LM, O'Connor FL, Crayton JW. Platelet cytosolic calcium responses to serotonin in depressed patients and controls: Relationship to symptomatology and medication. Biol Psychiatry 1998;43:327-34.
98. Berk M, Mitchell VS, Plein H. The platelet intracellular calcium response to serotonin in subsyndromal depression. Int Clin Psychopharmacol 1998; 13:107-10.
99. Brunello N, Racagni G. Rationale for the development of noradrenaline reuptake inhibitors. Human Psychopharmacol 1998;13:S13-9.
100. Carney RM, Rich MW, deVelde A, Saini J, Clark K, Freedland KE. Prevalence of major depressive disorder in patients receiving β-bloquer therapy versus other medications. Am J Med 1987;83:223-6.
101. Stahl S. 5HT1A receptors and pharmacotherapy. Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull 1994;30:39-43.
102. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-606.